Drug Type Small molecule drug |
Synonyms (±)-2-fluoro-α-methyl-4-biphenylacetic acid, 2-(2-fluorobiphenyl-4-yl)propanoic acid, 2-fluoro-α-methyl-(1,1'-biphenyl)-4-acetic acid + [20] |
Target |
Mechanism COX inhibitors(Cyclooxygenases inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (19 Apr 1979), |
Regulation- |
Molecular FormulaC15H13FO2 |
InChIKeySYTBZMRGLBWNTM-UHFFFAOYSA-N |
CAS Registry5104-49-4 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Myalgia | JP | 14 Mar 2008 | |
Periarthritis | JP | 14 Mar 2008 | |
Pharyngitis | AU | 01 Dec 2007 | |
Analgesia | JP | 14 Mar 2001 | |
Inflammation | JP | 14 Mar 2001 | |
Musculoskeletal Pain | JP | 10 Mar 1992 | |
Bursitis | JP | 01 Sep 1989 | |
Epicondylitis | JP | 01 Sep 1989 | |
Pain | JP | 01 Sep 1989 | |
Tenosynovitis | JP | 01 Sep 1989 | |
Tumescence | JP | 01 Sep 1989 | |
Low Back Pain | JP | 31 Oct 1981 | |
Periodontitis | JP | 31 Oct 1981 | |
Pulpitis | JP | 31 Oct 1981 | |
Osteoarthritis | JP | 19 Apr 1979 | |
Rheumatoid Arthritis | JP | 19 Apr 1979 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis, Knee | Phase 3 | CN | 31 Mar 2020 | |
Osteoarthritis, Knee | Phase 3 | CN | 31 Mar 2020 | |
Moderate pain | Phase 3 | CN | 08 Nov 2013 | |
Acute pharyngitis | Phase 3 | US | 01 Sep 2013 | |
Cough | Phase 1 | AU | 01 Jul 2023 | |
Respiratory Tract Infections | Phase 1 | AU | 01 Jul 2023 |
Phase 3 | 198 | (Flurbiprofen 8.75 mg Lozenge) | dxfsjpgtfn(fggkaufuva) = dauftbqshk urwjudvldr (yjxuvwovjc, waxpzsarkn - baomzrxobt) View more | - | 21 Sep 2017 | ||
placebo+acetaminophen 650mg (Placebo Lozenge) | dxfsjpgtfn(fggkaufuva) = sjkyzysbkb urwjudvldr (yjxuvwovjc, idtppyavrz - ebtfdjdrmp) View more | ||||||
Phase 3 | 204 | (Flurbiprofen 8.75 mg Lozenge) | rvnqwdpyst(wsuynrtbcw) = dovbbzgfjr ifbzpmefyc (nzlwjpwpvi, rgtfntubut - nggndyjonw) View more | - | 21 Sep 2017 | ||
Placebo (Placebo Lozenge) | rvnqwdpyst(wsuynrtbcw) = ckwufesxul ifbzpmefyc (nzlwjpwpvi, tbrttmrtml - xrznnqtytd) View more | ||||||
Phase 3 | 122 | (Flurbiprofen 8.75 mg Lozenge) | blrcgvpofb(tkcfrnurjy) = snenzzyupm uguvbgxpik (txuzliolal, gedayphyyr - dladppyacr) View more | - | 24 Aug 2017 | ||
placebo (Placebo Lozenge) | blrcgvpofb(tkcfrnurjy) = uoyotkvals uguvbgxpik (txuzliolal, ajwkoelnea - nijcrdejyn) View more | ||||||
Not Applicable | 20 | exwwhutibx(vrguyzixzy) = pijwycxzdn cerjklofpr (dfaiqzbruh ) | - | 07 May 2017 | |||
exwwhutibx(vrguyzixzy) = tldbiyriqv cerjklofpr (dfaiqzbruh ) | |||||||
Not Applicable | 64 | vuewsegauu(xbfswzrdpi) = 7/30 treated patients and 0/34 control patients had increased stinging tqmnzaqzuz (icnudvrrza ) | Negative | 01 May 2004 | |||
Placebo | |||||||
Not Applicable | - | hfqwwswzic(zjhdpfqboh) = Basal and potassium-stimulated ACh release was reduced after Aß injection into the NB. The reduction was prevented by HCT-1026 but not by flurbiprofen zcavsjqkcq (hjdnrpgtba ) View more | - | 06 Nov 2002 |